Lundbeck

Teva’s weak pipeline hit by Tourette’s drug trial failure

There are a few other candidates in development however, including Lundbeck’s mid-stage drug  ABX-1431, an MGLL inhibitor acquired along with Abide Therapeutics last year, Therapix’ tetrahydrocannabidiol-based

Allergan gets FDA nod for first oral CGRP drug for migraine

eptinezumab from Alder Biopharma – now  owned by Lundbeck – in late-stage development.

The mission matters

economics. As Deborah Dunsire, CEO of Lundbeck, put it, our industry demands a very high concentration of intellectual capital across a very wide range of disciplines.

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Other treatments targeting serotonin pathways in Alzheimer’s haven’t proved to be successful – such as Lundbeck and Otsuka’s 5-HT.

Darwinian leadership in the life sciences industry

Or, to use the crisper, to-the-point description given by Lundbeck’s Deborah Dunsire, to be a world-class life sciences company requires a very high concentration of intellectual capital

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]